Xtant Medical (NYSE: XTNT) posts 2026 annual meeting voting tallies

Q: What was the shareholder turnout at Xtant Medical (XTNT)'s 2026 annual meeting?

Turnout was based on 104,456,998 shares being present in person or represented by proxy, which was 74.47% of the 140,262,960 shares outstanding and entitled to vote as of June 9, 2026 at the August 7, 2026 meeting.

Q: How many XTNT common shares were entitled to vote at the 2026 annual meeting?

A total of 140,262,960 shares of Xtant Medical common stock were outstanding and entitled to vote as of the June 9, 2026 record date for the Annual Meeting held on August 7, 2026, with each share entitled to one vote.

Q: How many proposals were voted on at Xtant Medical (XTNT)'s 2026 annual meeting?

Stockholders voted on three proposals at the August 7, 2026 Annual Meeting. Detailed descriptions of each proposal are provided in the company’s definitive proxy statement dated June 23, 2026, while the reported results list vote totals for each of the three items.

Q: What were the voting results for the second proposal at Xtant Medical (XTNT)'s 2026 meeting?

The second proposal received 104,245,812 votes for, 30,112 votes against and 181,074 abstentions, with 0 broker non-votes reported. These totals reflect the shares present in person or by proxy and entitled to vote on that proposal.

Q: What were the voting results for the third proposal at Xtant Medical (XTNT)'s 2026 meeting?

The third proposal received 79,416,901 votes for, 1,030,090 votes against and 226,344 abstentions, along with 23,783,663 broker non-votes. These figures show how represented shares were cast on that proposal at the August 7, 2026 Annual Meeting.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Xtant Medical Holdings, Inc. reported voting results from its August 7, 2026 Annual Meeting of Stockholders.

There were 140,262,960 shares of common stock outstanding and entitled to vote as of June 9, 2026. Holders of 104,456,998 shares were present in person or represented by proxy, representing 74.47% of outstanding shares and constituting a quorum.

Stockholders voted on three proposals. For the first proposal, the individuals listed received between 79,590,709 and 80,450,301 votes for, with 23,783,663 broker non-votes recorded. A second proposal received 104,245,812 votes for, 30,112 against and 181,074 abstentions. A third proposal received 79,416,901 votes for, 1,030,090 against, 226,344 abstentions and 23,783,663 broker non-votes.

8-K Event Classification

2 items: 5.07, 9.01

2 items

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Shares outstanding: 140,262,960 shares Shares represented: 104,456,998 shares Meeting turnout: 74.47% +3 more

6 metrics

Shares outstanding 140,262,960 shares Common stock outstanding and entitled to vote as of June 9, 2026

Shares represented 104,456,998 shares Common shares present in person or by proxy at the Annual Meeting

Meeting turnout 74.47% Percentage of outstanding common shares represented at the Annual Meeting

First proposal broker non-votes 23,783,663 votes Broker non-votes recorded on the first voting item

Second proposal votes for 104,245,812 votes Votes cast in favor of the second proposal

Third proposal votes for 79,416,901 votes Votes cast in favor of the third proposal

Key Terms

broker non-votes, quorum, definitive proxy statement, emerging growth company

4 terms

broker non-votes financial

"Broker non-votes recorded for several proposals, including 23,783,663 broker non-votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

quorum financial

"representing 74.47% of the outstanding shares of Common Stock ... and which constituted a quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

definitive proxy statement financial

"each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

emerging growth company financial

"Emerging growth company Xtant Medical Holdings, Inc."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/07/2026 - 04:16 PM Accepted by SEC EDGAR 08/07/2026 - 04:15 PM

FAQ

What was the shareholder turnout at Xtant Medical (XTNT)'s 2026 annual meeting?

Turnout was based on 104,456,998 shares being present in person or represented by proxy, which was 74.47% of the 140,262,960 shares outstanding and entitled to vote as of June 9, 2026 at the August 7, 2026 meeting.

How many XTNT common shares were entitled to vote at the 2026 annual meeting?

A total of 140,262,960 shares of Xtant Medical common stock were outstanding and entitled to vote as of the June 9, 2026 record date for the Annual Meeting held on August 7, 2026, with each share entitled to one vote.

How many proposals were voted on at Xtant Medical (XTNT)'s 2026 annual meeting?

Stockholders voted on three proposals at the August 7, 2026 Annual Meeting. Detailed descriptions of each proposal are provided in the company’s definitive proxy statement dated June 23, 2026, while the reported results list vote totals for each of the three items.

What were the voting results for the second proposal at Xtant Medical (XTNT)'s 2026 meeting?

The second proposal received 104,245,812 votes for, 30,112 votes against and 181,074 abstentions, with 0 broker non-votes reported. These totals reflect the shares present in person or by proxy and entitled to vote on that proposal.

What were the voting results for the third proposal at Xtant Medical (XTNT)'s 2026 meeting?

The third proposal received 79,416,901 votes for, 1,030,090 votes against and 226,344 abstentions, along with 23,783,663 broker non-votes. These figures show how represented shares were cast on that proposal at the August 7, 2026 Annual Meeting.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2026

XTANT MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-34951

20-5313323

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

664 Cruiser Lane

Belgrade, Montana

59714

(Address of principal executive offices)

(Zip Code)

(406) 388-0480

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.000001 per share		XTNT		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

Xtant Medical Holdings, Inc. (the “Company”) held an Annual Meeting of Stockholders (the “Annual Meeting”) on August 7, 2026. As of the close of business on June 9, 2026, the record date for the Annual Meeting, there were 140,262,960 shares of the Company’s common stock, par value $0.000001 per share (the “Common Stock”), outstanding and entitled to vote at the Annual Meeting. Each share of Common Stock was entitled to one vote. Stockholders holding an aggregate of 104,456,998 shares of Common Stock entitled to vote at the Annual Meeting, representing 74.47% of the outstanding shares of Common Stock as of the record date, and which constituted a quorum thereof, were present in person or represented by proxy at the Annual Meeting.

At the Annual Meeting, the Company’s stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on June 23, 2026 (the “2026 Proxy Statement”). The final results of such stockholder voting on each proposal brought before the Annual Meeting are set forth below:

Proposal One -

Election of Directors. The six nominees proposed by the Company’s Board of Directors were elected to serve as directors until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified by the following final voting results:

	Votes For	Votes Withheld	Broker Non-Votes
John K. Bakewell	80,444,952	228,383	23,783,663
Jonn R. Beeson	79,698,307	975,028	23,783,663
Sean E. Browne	80,428,295	245,040	23,783,663
Abhinav Jain	80,335,481	337,854	23,783,663
Tyler P. Lipschultz	80,450,301	223,034	23,783,663
Stavros G. Vizirgianakis	79,590,709	1,082,626	23,783,663

Proposal Two -

Ratification of Appointment of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the following final voting results:

Votes For		Votes Against		Abstentions		Broker Non-Votes
104,245,812		30,112		181,074		0

Proposal Three -

Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s executive officers named in the 2026 Proxy Statement by the following final voting results:

Votes For		Votes Against		Abstentions		Broker Non-Votes
79,416,901		1,030,090		226,344		23,783,663

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		The Cover Page from this Current Report on Form 8-K, Formatted in Inline XBRL (filed herewith)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	XTANT MEDICAL HOLDINGS, INC.

	By:	/s/ Scott Neils
		Scott Neils
		Chief Financial Officer

Date: August 7, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents